

Adolor Corp. Fundamental Company Report Including Financial, SWOT, Competitors and Industry Analysis

https://marketpublishers.com/r/A45CF867600BEN.html

Date: May 2025

Pages: 50

Price: US\$ 499.00 (Single User License)

ID: A45CF867600BEN

Abstracts

Adolor Corp. Fundamental Company Report provides a complete overview of the company's affairs. All available data is presented in a comprehensive and easily accessed format. The report includes financial and SWOT information, industry analysis, opinions, estimates, plus annual and quarterly forecasts made by stock market experts. The report also enables direct comparison to be made between Adolor Corp. and its competitors. This provides our Clients with a clear understanding of Adolor Corp. position in the Pharmaceuticals and Biotechnology Industry.

The report contains detailed information about Adolor Corp. that gives an unrivalled in-depth knowledge about internal business-environment of the company: data about the owners, senior executives, locations, subsidiaries, markets, products, and company history.

Another part of the report is a SWOT-analysis carried out for Adolor Corp.. It involves specifying the objective of the company's business and identifies the different factors that are favorable and unfavorable to achieving that objective. SWOT-analysis helps to understand company's strengths, weaknesses, opportunities, and possible threats against it.

The Adolor Corp. financial analysis covers the income statement and ratio trendcharts with balance sheets and cash flows presented on an annual and quarterly basis. The report outlines the main financial ratios pertaining to profitability, margin analysis, asset turnover, credit ratios, and company's long-term solvency. This sort of company's information will assist and strengthen your



company's decision-making processes.

In the part that describes Adolor Corp. competitors and the industry in whole, the information about company's financial ratios is compared to those of its competitors and to the industry. The unique analysis of the market and company's competitors along with detailed information about the internal and external factors affecting the relevant industry will help to manage your business environment. Your company's business and sales activities will be boosted by gaining an insight into your competitors' businesses.

Also the report provides relevant news, an analysis of PR-activity, and stock price movements. The latter are correlated with pertinent news and press releases, and annual and quarterly forecasts are given by a variety of experts and market research firms. Such information creates your awareness about principal trends of Adolor Corp. business.

About Adolor Corp.

Adolor Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of prescription pain management products.

ENTEREG (alvimopan)

The company's primary product, ENTEREG (alvimopan), is a small molecule, peripherally-acting mu opioid receptor antagonist intended to block the adverse side effects of opioid analgesics on the gastrointestinal (GI) tract without affecting their beneficial analgesic effects. The company launched ENTEREG in collaboration with Glaxo Group Limited (Glaxo) in the United States. ENTEREG is specifically indicated to accelerate upper and lower GI recovery following partial large or small bowel resection surgery with primary anastomosis.

DEVELOPMENT PROGRAMS

The company also has various product candidates in various stages of clinical and preclinical development.

Delta Opioid Receptor Agonist Program: The company is pursuing development of these compounds as a potential new class of opioid analgesics that produce pain relief



similar to traditional mu opioids. It is collaborating with Pfizer Inc. (Pfizer) in the clinical development of two delta opioid receptor agonist compounds, ADL5859 and ADL5747 (Pfizer compounds PF-04856880 and PF-04856881, respectively), for the treatment of pain. In October 2009, Pfizer and the company initiated a Phase 2a proof-of-concept study of ADL5859 and ADL5747 in osteoarthritis (OA) patients. In January 2010, Pfizer and the company initiated a Phase 2a proof-of-concept study of ADL5747 in post-herpetic neuralgia (PHN).

Opioid Bowel Dysfunction Program: The company is also clinically testing ADL7445 and ADL5945 to treat opioid bowel dysfunction (OBD), a condition that often results from chronic use of opioid analgesics to treat persistent pain conditions. The company is conducting initial clinical evaluation of both compounds in parallel.

Other: The company's other product candidates are in preclinical development for treating moderate-to-severe pain and other central nervous system conditions.

Customers

The company's principal customers are wholesale drug distributors, such as Cardinal Health, Inc.; McKesson Corporation; and AmerisourceBergen Corporation.

Suppliers

The company's suppliers include Piramal Healthcare (Canada) Limited and Central Glass Germany GmbH.

History

Adolor Corporation was founded in 1993.

The above Company Fundamental Report is a half-ready report and contents are subject to change.

It means that we have all necessary data in our database to prepare the report but need **2-3 days** to complete it. During this time we are also updating the report with respect to the current moment. So, you can get all the most recent data available for the same price. Please note that preparation of additional types of analyses requires extra time.



Contents

RESEARCH METHODOLOGY

DISCLAIMER

1. ADOLOR CORP. COMPANY PROFILE

- 1.1. Key facts
- 1.2. Financial Performance
- 1.3. Key Executives
- 1.4. Ownership and Major Holders
- 1.5. Company History

2. ADOLOR CORP. BUSINESS OVERVIEW

- 2.1. Business Description
- 2.2. Major Products and Services
- 2.3. Markets and Sales Activities
- 2.4. Locations, Subsidiaries, Operating Units

3. ADOLOR CORP. SWOT ANALYSIS

- 3.1. Overview
- 3.2. Strengths
- 3.3. Weaknesses
- 3.4. Opportunities
- 3.5. Threats

4. ADOLOR CORP. FINANCIAL ANALYSIS

- 4.1. Financial Statements
- 4.1.1. Income Statement
- 4.1.2. Balance Sheet
- 4.1.3. Cash Flow
- 4.2. Financial Ratios
- 4.2.1. Profitability
- 4.2.2. Margin Analysis



- 4.2.3. Asset Turnover
- 4.2.4. Credit Ratios
- 4.2.5. Long-Term Solvency
- 4.2.6. Growth Over Prior Year
- 4.2.7. Financial Ratios Charts
- 4.3. Stock Market Snapshot

5. ADOLOR CORP. COMPETITORS AND INDUSTRY ANALYSIS

- 5.1. Adolor Corp. Direct Competitors
- 5.2. Comparison of Adolor Corp. and Direct Competitors Financial Ratios
- 5.3. Comparison of Adolor Corp. and Direct Competitors Stock Charts
- 5.4. Adolor Corp. Industry Analysis
- 5.4.1. Pharmaceuticals and Biotechnology Industry Snapshot
 - 5.4.2. Adolor Corp. Industry Position Analysis

6. ADOLOR CORP. NEWS & EVENTS

- 6.1. News & PR Activity Analysis
- 6.2. IR Corporate News
- 6.3. Marketing News
- 6.4. Corporate Events

7. ADOLOR CORP. EXPERTS REVIEW¹

- 7.1. Experts Consensus
- 7.2. Experts Revisions

8. ADOLOR CORP. ENHANCED SWOT ANALYSIS²

9. UNITED STATES PESTEL ANALYSIS²

- 9.1. Political Factors
- 9.2. Economic Factors
- 9.3. Social Factors
- 9.4. Technological Factors
- 9.5. Environmental Factors
- 9.6. Legal Factors



10. ADOLOR CORP. IFE, EFE, IE MATRICES²

- 10.1. Internal Factor Evaluation Matrix
- 10.2. External Factor Evaluation Matrix
- 10.3. Internal External Matrix
- 11. ADOLOR CORP. PORTER FIVE FORCES ANALYSIS²
- 12. ADOLOR CORP. VRIO ANALYSIS²

APPENDIX: RATIO DEFINITIONS

LIST OF FIGURES

Adolor Corp. Annual Revenues in Comparison with Cost of Goods Sold and Gross Profit

Profit Margin Chart

Operating Margin Chart

Return on Equity (ROE) Chart

Return on Assets (ROA) Chart

Debt to Equity Chart

Current Ratio Chart

Adolor Corp. 1-year Stock Charts

Adolor Corp. 5-year Stock Charts

Adolor Corp. vs. Main Indexes 1-year Stock Chart

Adolor Corp. vs. Direct Competitors 1-year Stock Charts

Adolor Corp. Article Density Chart

The complete financial data is available for publicly traded companies.

^{1 –} Data availability depends on company's security policy.

^{2 –} These sections are available only when you purchase a report with appropriate additional types of analyses.



List Of Tables

LIST OF TABLES

Adolor Corp. Key Facts

Profitability

Management Effectiveness

Income Statement Key Figures

Balance Sheet Key Figures

Cash Flow Statement Key Figures

Financial Performance Abbreviation Guide

Adolor Corp. Key Executives

Adolor Corp. Major Shareholders

Adolor Corp. History

Adolor Corp. Products

Revenues by Segment

Revenues by Region

Adolor Corp. Offices and Representations

Adolor Corp. SWOT Analysis

Yearly Income Statement Including Trends

Income Statement Latest 4 Quarters Including Trends

Yearly Balance Sheet Including Trends

Balance Sheet Latest 4 Quarters Including Trends

Yearly Cash Flow Including Trends

Cash Flow Latest 4 Quarters Including Trends

Adolor Corp. Profitability Ratios

Margin Analysis Ratios

Asset Turnover Ratios

Credit Ratios

Long-Term Solvency Ratios

Financial Ratios Growth Over Prior Year

Adolor Corp. Capital Market Snapshot

Adolor Corp. Direct Competitors Key Facts

Direct Competitors Profitability Ratios

Direct Competitors Margin Analysis Ratios

Direct Competitors Asset Turnover Ratios

Direct Competitors Credit Ratios

Direct Competitors Long-Term Solvency Ratios

Pharmaceuticals and Biotechnology Industry Statistics



Adolor Corp. Industry Position

Company vs. Industry Income Statement Analysis

Company vs. Industry Balance Sheet Analysis

Company vs. Industry Cash Flow Analysis

Company vs. Industry Ratios Comparison

Adolor Corp. Consensus Recommendations¹

Analyst Recommendation Summary¹

Price Target Summary¹

Experts Recommendation Trends¹

Revenue Estimates Analysis¹

Earnings Estimates Analysis¹

Historical Surprises¹

Revenue Estimates Trend¹

Earnings Estimates Trend¹

Revenue Revisions¹



ANALYSIS FEATURES

SWOT Analysis

SWOT, which stands for Strengths, Weaknesses, Opportunities and Threats, is an analytical framework that identifies the internal and external factors that are favorable and unfavorable for a company.

Enhanced SWOT Analysis

Enhanced SWOT is a 3×3 grid that arranges strengths, weaknesses, opportunities and threats into one scheme:

How to use the strengths to take advantage of the opportunities?

How to use the strengths to reduce likelihood and impact of the threats?

How to overcome the weaknesses that obstruct taking advantage of the opportunities?

How to overcome the weaknesses that can make the threats a reality?

Upon answering these questions a company can develop a project plan to improve its business performance.

PESTEL Analysis

PESTEL (also termed as PESTLE) is an ideal tool to strategically analyze what influence different outside factors – political, economic, sociocultural, technological, environmental and legal – exert on a business to later chart its long term targets.

Being part of the external analysis when carrying out a strategic assessment or performing a market study, PESTEL gives an overview of diverse macro-environmental factors that any company should thoughtfully consider. By perceiving these outside environments, businesses can maximally benefit from the opportunities while minimizing the threats to the organization.



Key Factors Examined by PESTEL Analysis:

Political – What opportunities and pressures are brought by political bodies and what is the degree of public regulations' impact on the business?

Economic – What economic policies, trends and structures are expected to affect the organization, what is this influence's degree?

Sociological – What cultural and societal aspects will work upon the demand for the business's products and operations?

Technological – What impact do the technological aspects, innovations, incentives and barriers have on the organization?

Environmental – What environmental and ecological facets, both locally and farther afield, are likely to predetermine the business?

Legal – What laws and legislation will exert influence on the style the business is carried out?

IFE, EFE, IE Matrices

The Internal Factor Evaluation matrix (IFE matrix) is a strategic management tool helping audit or evaluate major weaknesses and strengths in a business's functional areas. In addition, IFE matrix serves as a basis for identifying and assessing relationships amongst those areas. The IFE matrix is utilised in strategy formulation.

The External Factor Evaluation matrix (EFE matrix) is a tool of strategic management that is typically utilised to assess current market conditions. It is an ideal instrument for visualising and prioritising the threats and opportunities a firm is facing.

The essential difference between the above mentioned matrices lies in the type of factors incorporated in the model; whilst the latter is engaged in internal factors, the former deals exceptionally with external factors – those exposed to social, political, economic, legal, etc. external forces.

Being a continuation of the EFE matrix and IFE matrix models, the Internal External matrix (IE matrix) rests upon an investigation of external and internal business factors



integrated into one suggestive model.

Porter Five Forces Analysis

The Porter's five forces analysis studies the industry of operation and helps the company find new sources of competitive advantage. The analysis surveys an industry through five major questions:

What composes a threat of substitute products and services?

Is there a threat of new competitors entering the market?

What is the intensity of competitive rivalry?

How big is the bargaining power of buyers?

How significant is the bargaining power of suppliers?

VRIO Analysis

VRIO stands for Value, Rarity, Imitability, Organization. This analysis helps to evaluate all company's resources and capabilities and bring them together into one aggregate table that includes:

Tangible resources

Financial

Physical

Technological

Organizational

Intangible resources

Human

Innovation and Creativity



Reputation

Organizational capabilities

The result of the analysis gives a clear picture of company's competitive and economic implications, answering the questions if the resources mentioned above are:

Valuable?
Rare?
Costly to imitate?
Organized properly?



I would like to order

Product name: Adolor Corp. Fundamental Company Report Including Financial, SWOT, Competitors and

Industry Analysis

Product link: https://marketpublishers.com/r/A45CF867600BEN.html

Price: US\$ 499.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/A45CF867600BEN.html